How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
78
OPGN Quote, Financials, Valuation and Earnings
Last price:
$25.5000
Seasonality move
:
32.23%
Day range:
$20.0100 - $27.6000
52-week range:
$0.0000 - $27.6000
Dividend yield:
0%
P/E ratio:
63.77x
P/S ratio:
28.63x
P/B ratio:
25.28x
Volume:
1.5K
Avg. volume:
6.2K
1-year change:
1940%
Market cap:
$256.8M
Revenue:
$5.2M
EPS (TTM):
$0.40
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, OpGen, Inc. has 17.65% upside to fair value with a price target of -- per share.
OPGN vs. S&P 500
-
Over the past 5 trading days, OpGen, Inc. has overperformed the S&P 500 by 41.8% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
OpGen, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
OpGen, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter OpGen, Inc. reported revenues of --.
Earnings Growth
-
OpGen, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter OpGen, Inc. reported earnings per share of -$0.06.
Enterprise value:
258.5M
EV / Invested capital:
--
Price / LTM sales:
28.63x
EV / EBIT:
38.84x
EV / Revenue:
28.72x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-213.47x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
37.79x
Gross Profit (TTM):
$8.8M
Return On Assets:
67.58%
Net Income Margin (TTM):
76.04%
Return On Equity:
89.47%
Return On Invested Capital:
70.06%
Operating Margin:
-5526.11%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $3.1M | $1.3M | $9M | -- | -- | |
| Gross Profit | $203.1K | -$32.5K | $8.8M | -$44.3K | -$48.1K | |
| Operating Income | -$18.4M | -$6M | $6.7M | -$783.9K | -$702.2K | |
| EBITDA | -$16.9M | -$5.6M | $6.8M | -$739.6K | -$654.1K | |
| Diluted EPS | -$65.21 | -$12.96 | $0.40 | $1.35 | -$0.06 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $29.8M | $13.4M | $3.5M | $3.2M | $5.5M | |
| Total Assets | $62.3M | $33M | $18.1M | $5.5M | $12.6M | |
| Current Liabilities | $19.2M | $12M | $12.5M | $589.8K | $782.5K | |
| Total Liabilities | $29M | $19M | $15.5M | $2.5M | $2.5M | |
| Total Equity | $33.3M | $13.9M | $2.7M | $3M | $10.2M | |
| Total Debt | $24.2M | $15.1M | $12M | $1.9M | $1.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.6M | -$6.3M | -$1.2M | -$2.8M | -$333.3K | |
| Cash From Investing | -$1.2M | -$900 | -- | -- | -- | |
| Cash From Financing | $7.3M | $7.2M | -$8K | $4.3M | -$84.1K | |
| Free Cash Flow | -$17.8M | -$6.3M | -$1.2M | -$2.8M | -$333.3K | |
OPGN
Sector
Market Cap
$256.8M
$23.4M
Price % of 52-Week High
92.39%
48.49%
Dividend Yield
0%
0%
Shareholder Yield
226441.47%
-1.67%
1-Year Price Total Return
1940%
-23.18%
Beta (5-Year)
-3,423.037
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$21.1863
200-day SMA
Buy
Level
$5.5995
Bollinger Bands (100)
Buy
Level
0.4729 - 15.9529
Chaikin Money Flow
Sell
Level
-3.2K
20-day SMA
Buy
Level
$19.3890
Relative Strength Index (RSI14)
Buy
Level
75.3741
ADX Line
Buy
Level
29.4808
Williams %R
Sell
Level
-16.6799
50-day SMA
Buy
Level
$15.0309
MACD (12, 26)
Buy
Level
6.3461
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
13.8K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-39.3078)
Sell
CA Score
(Annual)
Level (-3.7408)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-15.1103)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.
Stock Forecast FAQ
In the current month, OPGN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OPGN average analyst price target in the past 3 months is --.
-
Where Will OpGen, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that OpGen, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About OpGen, Inc.?
Analysts are divided on their view about OpGen, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that OpGen, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is OpGen, Inc.'s Price Target?
The price target for OpGen, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OPGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for OpGen, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of OPGN?
You can purchase shares of OpGen, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase OpGen, Inc. shares.
-
What Is The OpGen, Inc. Share Price Today?
OpGen, Inc. was last trading at $25.5000 per share. This represents the most recent stock quote for OpGen, Inc.. Yesterday, OpGen, Inc. closed at $25.5000 per share.
-
How To Buy OpGen, Inc. Stock Online?
In order to purchase OpGen, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get OPGN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
OPGN
Sector
P/E ratio
63.77x
23.40x
PEG ratio
--
-0.01x
P/B ratio
25.28x
1.74x
Price / LTM sales
28.63x
1.48x
Growth Metrics
OPGN
Sector
Revenue growth
-96.2%
3.36%
Earnings growth
-104.47%
9.35%
Revenue (5-year growth)
8.23%
6.22%
Earnings forecast
--
-$0.19
Profitability
OPGN
Sector
Profitability FY 2024
$5M
$2.7M
Return on invested capital
70.06%
-33.62%
Return on assets
67.58%
-29.68%
Return on equity
89.47%
-38.98%
Earnings Date
Last Earnings Date
Nov
14
Next Earnings Date
Feb
7
Estimated Next Earnings Date
May
9
Balance Sheet
OPGN
Sector
Total cash
$414.2K
$25M
Short term investments
--
$23.9M
Total assets
$9.9M
$72.5M
Long term debt
$1.7M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
